BaselArea

Dreispitz-Areal, Basel/Münchenstein

Mon, 30 Jan 2012 11:54:00 +0100

A new urban district in the making: The Dreispitz area is one of the largest development projects in Switzerland. It connects to downtown Basel in the north and spreads over an area of approximately 50 football pitches to the south, half each in the cantons Basel-Stadt and Baselland. It is easily accessible to commercial, private and public transport, owing to its long history as an area used mainly for logistics and business.

The Christoph Merian Foundation is the sole landowner of Dreispitz and promotes its development by granting building rights. This development aims at transforming parts of this already attractive logistics and business plot into a modern and vibrant multi-use city district with a distinct identity. It will combine business, residential and leisure areas as well as culture and shopping. In addition to the already existing 400 businesses, the potential for nearly 6'000 new jobs will be created through concentration and densification, and in addition to that, apartments will be available for some 2'500 residents.

As regards the urban development, this transformation is led by a vision created by the renowned architects Herzog & de Meuron. Since 2009 this vision is being put into practice: For an area that comprises around a tenth of the whole of Dreispitz, the former "Zollfreilager" (where in the past goods in transit were stored duty free), there already is an authoritative development plan in place. All in all 300 residences are being created in this new area now called the "KunstFreilager". An arts college as well as various institutions and players from the arts and creative industries have already taken a front seat in this development as pioneers and trendsetters and have moved to Dreispitz. Notably two projects have been instrumental in realizing the KunstFreilager: The "Dreispitzhalle", an indoor event venue, and the art-, studio- and business complex "Oslo". But besides developing infrastructure and buildings there is also much consideration for public spaces and green areas.

Find more information at: www.dreispitz.ch

Contact:
Christoph Merian Stiftung
Herr Felix Leuppi
St. Alban-Vorstadt 5
Postfach
4002 Basel
Tel. +41 61 226 33 16
f.leuppianti spam bot@dreispitzanti spam bot.ch

Schild site, Liestal

Fri, 16 Dec 2011 10:10:00 +0100

Building
The new four-story building is ideal for production, trade, offices, laboratories and training. The building is a core and shell construction and offers great flexibility with the tenant-specific interior finish in terms of subdivision and materials.
The building is fitted with a personnel and goods elevator, loading bays and an underground car park for 50 cars

Leasable areas
420 to 3800 m2, flexibility of interior finish allowing the area to be divided up according to the tenant’s needs

Infrastructure
The Schild site offers a wide range of energy supplies - including not only basic supplies, but also process heat, compressed air and groundwater, as required.
The public restaurant “Im Schild” with seating for over 150 people offers a diverse range of menus and beverages at low cost.

Schild site – the location
The Schild site is conveniently located on the outskirts of Liestal with a direct link to the new highway H2, 13 km from Basel.
The Schild site is home to over 50 companies from a wide variety of sectors occupying 8 buildings.

Leasing

Schild AG Liestal
Marc Löhle
Eichenweg 1
CH-4410 Liestal
Tel. 061 906 97 92
liegenschaftenanti spam bot@schildanti spam bot.ch

Basel and Miami Beach Sign the City Partnership Agreement

Mon, 28 Nov 2011 00:00:00 +0100

Basel and Miami Beach have shared close ties for a decade already. These ties will be formalised in the form of a city partnership agreement today, Monday November 28 2011, which will be signed at a ceremony at Miami Beach City Hall. The foundation of the agreement was laid during Art 42 Basel in June, when President Guy Morin and Matti Herrera Bower signed a Memorandum of Understanding at Basel City Hall.

It is no coincidence that the signing takes place just before Art Basel Miami Beach kicks off this year to celebrate its 10th anniversary. The regular exchanges between the two cultural capitals go back to the first Art Basel Miami Beach in the year 2002. Since then, the two cities have continually intensified their relationship. For Basel-Stadt, today’s signing of the official partnership treaty is also a confirmation of MCH Group’s commitment to Miami Beach as a business location.

The cities’ extensive common interests in the cultural field are at the heart of the partnership arrangement. Furthermore, strategic cooperation will also be promoted in the economic, trade, education and research fields. The city partnership model represents a platform for lively exchanges between all actors interested in these areas.

Extension of the global network
Basel is already twinned with the State of Massachusetts and the city of Shanghai, China. Building on mutual strengths, city partnerships represent an integral part of the activities performed by the Department of Presidential Affairs that have both a direct and an indirect impact on the positive development of the cities involved. Similar to Basel, the southern US city of Miami Beach is also the site of numerous cultural events, ranging from exhibitions of classic collections and modern art to ballet performances and concerts.

The Art Basel Miami Beach show is one of the most prominent art events in the United States. With its additional thriving clusters in the fields or tourism, business development and education, Miami Beach is an inspiring partner city and a welcome addition to Basel’s global network. Miami Beach has entered into over ten of such partnerships, with Basel being the only partner city in the central European region.

For further information, please contact:
Sabine Horvath
Leiterin Aussenbeziehungen und Standortmarketing Basel-Stadt
Phone +41 (0)61 267 40 87
Mobile: +41 (0)79 623 30 14
E-mail: sabine.horvathanti spam bot@bsanti spam bot.ch

react LabCenter, Basel-Süd

Fri, 16 Dec 2011 10:12:00 +0100

Requested size: up to 12,000 m². Modular and practice-oriented installations. Occupancy as agreed.

Rarely cheap: reasonable tax burden in the Basel-Land canton with the locational advantage of being in Switzerland. Transparent and calculable costs. Location with ideal transportation connections.

In good company: Chemicals and pharmaceuticals industry cluster. Potential for bio, nano and clean technologies. Close proximity to universities. A functioning labour market with a domestic and international labour force.

Swiss Quality: Politically and economically stable situation, quiet working environment, reliable infrastructure.

For detailed information go to www.react-basel.ch./ensmeyersImmobilien ⋅ ManagementPatrick NäpflinDornachersterasse 230CH-4053 BaselTel. +41 (0)58 322 88 71Fax +41 (0)58 322 88 90patrick.naepflin@smeyers.ch

BioVersys AG receives the 2011 Swiss Technology Award

Mon, 07 Nov 2011 11:43:00 +0100

BioVersys won in the Start-Up category for its innovative technology to identify small molecules that has the potential to “switch off” antibiotic resistances in bacterial pathogens. “We are very honored to win this prestigious prize. It is recognition of our technology and motivates our entire team to continue working towards overcoming the rising threat of drug resistant bacterial infections.” stated Dr. Marc Gitzinger (CEO) and Dr. Marcel Tigges (CSO).

“This award is testimony to the pioneering nature of the BioVersys technology which represents an exciting novel approach towards achieving new anti-bacterial therapies as well as the potential to rejuvenate older, proven, safe and inexpensive antibiotics. In a world saturated with expensive medicines, this pioneering work may help address the escalating costs of healthcare in antiinfectives
by making obsolete antibiotics relevant again.” said Dr. Seng Chin Mah, Chairman of the Board.

Dr. Peter Burckhardt, CEO of EVA and President of BioValley Business Angels Club BioBAC, comments: “We are proud of BioVersys. The award is an external validation of our efforts in coaching and financing of spin-offs who translate scientific results into business.”

BioVersys AG is a privately held biopharmaceuticals company. It is a spin-off company from the ETH Zurich located in Basel. The company focuses on the research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and thus restore the efficacy of existing antibiotics. (www.bioversys.com)

Swiss Technology Award Switzerland’s leading technology award presents the most innovative companies and promotes the innovate power of Switzerland. Initiated by Nicholas Hayek and Branko Weiss the award can look back on a long tradition and track record: Since 1987 over 1900 projects applied and about 370 winners were awarded. (www.swiss-innovation.com/award)

Media contact:
Dr. Marc Gitzinger
E-mail: infoanti spam bot@bioversysanti spam bot.com
Tel: +41 61 633 22 50

Canyon Pharmaceuticals Honored with Frost & Sullivan Award for Product Differentiation Excellence in Parenteral Anticoagulants

Thu, 27 Oct 2011 12:22:00 +0200

“Iprivask has been shown to prevent thrombosis significantly more effectively than the standard of care, with no increase in bleeding risk. A simplified fixed dose regimen and easy subcutaneous administration coupled with an attractive pharmacological profile make Iprivask ideally suited for the acute care setting, a space in need of safe, effective and user friendly therapies. Through careful product differentiation during development, Canyon Pharmaceuticals has succeeded in uniquely positioning Iprivask to be very competitive in an increasingly crowded market,” noted Frost & Sullivan Analyst Debbie Toscano.

“Our mission at Canyon Pharmaceuticals is to connect people and science to deliver life-saving medicines that serve today’s unmet needs,” notes Dawn Bell, PharmD, Senior Vice President and General Manager of Canyon’s US subsidiary. “We worked closely with our acute-care physician and pharmacy colleagues to understand the gaps with current therapies and subsequently launched a highly differentiated anticoagulant that serves critical unmet needs in the hospitalized patient.”

“To achieve this recognition is truly gratifying and a testament to the important unmet needs in the anticoagulant marketplace that Iprivask is able to address,” says Seng Chin Mah, CEO of Canyon Pharmaceuticals Group AG.

About Canyon

Canyon PharmaceuticalsTM is a privately held specialty biopharmaceutical company focused on delivering innovative therapeutic solutions that target important cellular pathways in thrombosis, tumor growth, and metastasis. Canyon holds exclusive world-wide rights to desirudin, a subcutaneous (SC) recombinant direct thrombin inhibitor (DTI), and to pegmusirudin, a pegylated recombinant DTI with a longer duration of action than desirudin.

Media Contact:
Dr. Seng Chin Mah
E-mail: seng_chin.mahanti spam bot@canyonpharmaanti spam bot.com
Tel: +41 61 201 1383
http://www.canyonpharma.com/

Abbott in Allschwil (BL) wins Tell Award

Thu, 27 Oct 2011 11:49:00 +0200

The most significant expansion project award for 2010 goes to Illinois‐based Abbott, the global
health care company, for its new Established Products Division (EPD) in Allschwil, canton Basel
Land. This division focuses on developing, manufacturing and providing access to established
pharmaceuticals in many international markets outside the USA. The new business in Allschwil
incorporates the EPD senior leadership team, Global Marketing, Development, Supply Chain
and Quality Assurance functions and currently employs about 270 persons, having added more
than 100 employees in the last year.

Iris Welten devient la nouvelle directrice de BaselArea

Tue, 13 Sep 2011 21:43:00 +0200

Iris Welten (43 ans) est, depuis 2005, maître de conférence du cursus « Master in Corporate Finance » à l’Université des Sciences appliquées de la Suisse du Nord-Ouest. Cette année, elle prépare également sa dissertation à l’Université de Zurich et poursuit un projet de recherche à l’Université des Sciences appliquées de la Suisse du Nord-Ouest.

Jusqu’en 2009, elle fut membre de la direction élargie de la société Zur Rose SA à Frauenfeld en tant que responsable du département Corporate Services. Dans cette fonction, elle était responsable des secteurs développement commercial, communication et qualité. Auparavant, Iris Welten a travaillé pour Swiss Life comme responsable des « Investor relations », pour Clariant, ainsi que pour Deutsche Telekom à New York. Madame Welten a étudié les sciences de l’information et de la communication, l’économie d’entreprise et la psychologie de marché à l’Université Ludwig Maximilian de Munich. Elle est mariée et habite à Pfeffingen, Bâle-Campagne.

Le Comité directeur de BaselArea est convaincu d’avoir trouvé en la personne d’Iris Welten une Directrice Générale qui fera profiter l’organisation de son expérience dans les domaines de la communication, de la stratégie et des finances. Il accueille Madame Welten cordialement et lui souhaite beaucoup de succès dans ses nouvelles fonctions.

BaselArea est responsable de la promotion internationale de la région économique de Bâle. Avec cette politique commune d’encouragement de l’économie, les cantons de Bâle-Ville, Bâle-Campagne et du Jura apportent leur soutien aux firmes étrangères lors de leur implantation dans la région et conseillent les créateurs de nouvelles entreprises. Les services de BaselArea sont offerts gracieusement à tous les intéressés. L’équipe de BaselArea conseille annuellement près de 500 clients et soutient la création ou l’implantation d’environ 80 sociétés.

Pour plus d'informations: Dr. Peter Krebser, Président BaselArea, Tèl. 079 432 39 24, krebser.peteranti spam bot@ch.sikaanti spam bot.com

FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of skin cancer

Wed, 17 Aug 2011 15:55:00 +0200

Roche today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by an FDA-approved test. The FDA today also approved the cobas 4800 BRAF V600 Mutation Test, a diagnostic test developed by Roche to identify patients eligible for treatment.

Zelboraf is the first and only FDA-approved personalized medicine shown to improve survival in people with BRAF V600E mutation-positive metastatic melanoma, demonstrating the benefits of Roche’s personalized healthcare approach. It is designed to target and inhibit some mutated forms of the BRAF protein found in about half of all cases of melanoma, the deadliest and most aggressive form of skin cancer.

“The FDA approval of Zelboraf marks a major step forward in personalizing the treatment of metastatic melanoma, a devastating disease that until this year had limited approved treatment options,” said Hal Barron, M.D., chief medical officer and head, Global Product Development. “We will continue to study this medicine with a goal of further improving outcomes for people with melanoma and other cancers that are driven by BRAF mutations.”

For more information: www.roche.com

Uferstrasse 90, Basel

Thu, 11 Aug 2011 11:20:00 +0200

Uferstrasse 90 is a modern, functional office complex. The building was extensively renovated in 2010 - 2011: warehouse space has been transformed into high-quality offices with spacious access areas. The original industrial character of the building was deliberately preserved.

The result is a building with an attractive loft character. This is especially apparent in the lobby: design furniture and metre-high lights greet the visitor in a 500 m2 hall, where trucks and forklifts once operated. Offices on the 1st floor are accessed via a gallery. The character of the whole building is informed by the architectural features of tall glass windows and visible load-bearing concrete pillars.

Twenty companies of various sizes are renting space at Uferstrasse 90. A total of 600 - 800 people from pharmaceuticals, tourism, fashion and clothing and the services sector are represented here. Altogether the building offers 13,000 m2 floor space spread over seven floors.

Detailed information can be found at www.uferstrasse90.ch

Your contact partner:

Grisard Management AG
Frau Yvonne Sutter
Uferstrasse 90
4019 Basel
Tel. 061 638 44 83
yvonnesutteranti spam bot@grisardanti spam bot.ch